JP2012097094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012097094A5 JP2012097094A5 JP2011268234A JP2011268234A JP2012097094A5 JP 2012097094 A5 JP2012097094 A5 JP 2012097094A5 JP 2011268234 A JP2011268234 A JP 2011268234A JP 2011268234 A JP2011268234 A JP 2011268234A JP 2012097094 A5 JP2012097094 A5 JP 2012097094A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- backbone
- gly
- arg
- negatively charged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 15
- 230000008685 targeting Effects 0.000 claims description 8
- 238000003384 imaging method Methods 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 108010039918 Polylysine Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229920000656 polylysine Polymers 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 8
- 230000037317 transdermal delivery Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 108091005948 blue fluorescent proteins Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22024400P | 2000-07-21 | 2000-07-21 | |
| US60/220,244 | 2000-07-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002513506A Division JP5610659B2 (ja) | 2000-07-21 | 2001-07-20 | 多成分生物学的輸送システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012097094A JP2012097094A (ja) | 2012-05-24 |
| JP2012097094A5 true JP2012097094A5 (enExample) | 2013-02-21 |
| JP5797104B2 JP5797104B2 (ja) | 2015-10-21 |
Family
ID=22822714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002513506A Expired - Fee Related JP5610659B2 (ja) | 2000-07-21 | 2001-07-20 | 多成分生物学的輸送システム |
| JP2011268234A Expired - Lifetime JP5797104B2 (ja) | 2000-07-21 | 2011-12-07 | 多成分生物学的輸送システム |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002513506A Expired - Fee Related JP5610659B2 (ja) | 2000-07-21 | 2001-07-20 | 多成分生物学的輸送システム |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7807780B2 (enExample) |
| EP (2) | EP1301213B1 (enExample) |
| JP (2) | JP5610659B2 (enExample) |
| AU (4) | AU8466501A (enExample) |
| CA (2) | CA2797652C (enExample) |
| CY (2) | CY1118963T1 (enExample) |
| DK (2) | DK1301213T3 (enExample) |
| ES (1) | ES2617692T3 (enExample) |
| IL (2) | IL154044A0 (enExample) |
| NZ (1) | NZ523719A (enExample) |
| PT (2) | PT2364734T (enExample) |
| WO (1) | WO2002007773A2 (enExample) |
| ZA (1) | ZA200300513B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750216B2 (en) | 1996-03-08 | 2004-06-15 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| US6239154B1 (en) | 1996-03-08 | 2001-05-29 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
| US6303611B1 (en) | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| US5763445A (en) | 1996-03-08 | 1998-06-09 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
| US20080281041A1 (en) | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| JP2003514564A (ja) * | 1999-11-24 | 2003-04-22 | エムシーエス マイクロ キャリア システムズ ゲーエムベーハー | 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法 |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| CA2797652C (en) | 2000-07-21 | 2016-03-08 | Revance Therapeutics, Inc. | Multi-component biological transport systems |
| WO2003072049A2 (en) * | 2002-02-21 | 2003-09-04 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
| US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
| ATE494010T1 (de) | 2002-02-27 | 2011-01-15 | Pharmain Corp | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung |
| US20050260259A1 (en) | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US7714015B2 (en) * | 2003-08-07 | 2010-05-11 | Lil Brat Pharmaceuticals Of Marlette, Mi | Method and composition for treating sunburned skin |
| DE10355559A1 (de) * | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| PT1729821E (pt) | 2004-03-03 | 2013-10-23 | Revance Therapeutics Inc | Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas |
| AU2005251676B2 (en) * | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| AU2011202928B2 (en) * | 2004-03-03 | 2013-01-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
| US8022179B2 (en) | 2005-03-03 | 2011-09-20 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| JP2009520040A (ja) | 2005-12-19 | 2009-05-21 | ファーマイン コーポレーション | 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法 |
| CA2638915A1 (en) * | 2006-02-10 | 2007-08-23 | The Regents Of The University Of California | Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps |
| US8454935B2 (en) * | 2006-07-12 | 2013-06-04 | Case Western Reserve University | Cell permeable probe |
| BRPI0715375A2 (pt) * | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
| US20100021502A1 (en) * | 2006-12-28 | 2010-01-28 | Waugh Jacob M | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT |
| CN102988995A (zh) * | 2006-12-29 | 2013-03-27 | 雷文斯治疗公司 | 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法 |
| EP2178549B1 (en) * | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US8563527B2 (en) | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
| US20090176892A1 (en) * | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
| KR101609894B1 (ko) | 2008-03-14 | 2016-04-08 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| HRP20180739T1 (hr) * | 2008-12-31 | 2018-06-29 | Revance Therapeutics, Inc. | Injekcijske formulacije botulinskog toksina |
| CA2766521C (en) | 2009-06-25 | 2020-07-21 | Revance Therapeutics, Inc. | Albumin-free botulinum toxin formulations |
| JP5951490B2 (ja) * | 2009-10-21 | 2016-07-13 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
| US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
| CA2880869A1 (en) | 2012-08-20 | 2014-02-27 | The Regents Of The University Of California | Polynucleotides having bioreversible groups |
| MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
| WO2015089487A1 (en) * | 2013-12-12 | 2015-06-18 | Life Technologies Corporation | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| JP6880526B2 (ja) * | 2015-02-27 | 2021-06-02 | 学校法人常翔学園 | 膜透過性ペプチドを側鎖に有する高分子化合物 |
| KR101666934B1 (ko) * | 2015-03-05 | 2016-10-17 | 한국유니온제약 주식회사 | 개량형 TAT 펩타이드가 융합된 EGF, 티모신β4, hGH 단백질의 생산방법 및 이들 단백질을 포함하는 화장료 조성물 |
| KR101993844B1 (ko) * | 2016-07-20 | 2019-06-27 | 한국유니온제약 주식회사 | 개량형 TAT 펩타이드가 융합된 EGF 또는 hGH 단백질의 생산방법 및 이들 단백질을 포함하는 화장료 조성물 |
| WO2019046311A1 (en) | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
| EP3753568A1 (en) | 2019-06-21 | 2020-12-23 | Fastox Pharma SA | Composition modulating botulinum neurotoxin effect |
| WO2025064729A1 (en) | 2023-09-19 | 2025-03-27 | Revance Therapeutics, Inc. | Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434228A (en) | 1982-04-20 | 1984-02-28 | Genex Corporation | Immobilization of biological materials in condensed polyalkyleneimine polymers |
| DE3486053T3 (de) | 1983-10-20 | 2004-01-08 | The Research Foundation Of State University Of New York | Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS. |
| FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| US4816568A (en) | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
| FR2602790B1 (fr) | 1986-08-13 | 1990-06-01 | Transgene Sa | Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante |
| MC2115A1 (fr) | 1987-12-15 | 1991-07-05 | Gene Shears Pty Ltd | Ribozynes |
| US5252713A (en) | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
| US5420105A (en) | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
| US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| ES2095959T3 (es) | 1990-10-24 | 1997-03-01 | Allelix Biopharma | Inhibidores de la replicacion del virus vih a base de peptidos. |
| US5190873A (en) * | 1991-06-21 | 1993-03-02 | California Institute Of Biological Research | Hybrid tryptophan aporepressor containing ligand binding sites |
| GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| JP2702285B2 (ja) * | 1992-08-21 | 1998-01-21 | バイオジェン，インコーポレイテッド | Ｔａｔ由来の輸送ポリペプチド |
| US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| US5484720A (en) * | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| US6232295B1 (en) * | 1994-10-12 | 2001-05-15 | Jon Faiz Kayyem | Cell-specific contrast agent and gene delivery vehicles |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9600272D0 (en) | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
| JP2000509394A (ja) | 1996-05-01 | 2000-07-25 | アンティバイラルズ インコーポレイテッド | 細胞膜を横切って物質を輸送するためのポリペプチド結合体 |
| GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
| FR2755976B1 (fr) | 1996-11-15 | 1999-01-15 | Idm Immuno Designed Molecules | Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires |
| US5794496A (en) | 1996-12-05 | 1998-08-18 | Hand Tool Design Corporation | Pawl module for ratchet wrench |
| DE69841937D1 (de) * | 1997-04-21 | 2010-11-25 | California Inst Of Techn | Multifunctionelle polymer-beschichtung |
| AU734827B2 (en) | 1997-05-21 | 2001-06-21 | Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| EP1030927A1 (en) * | 1997-11-12 | 2000-08-30 | Valentis Inc. | Expression plasmids for multiepitope nucleic acid-based vaccines |
| US5985434A (en) | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
| WO1999029721A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| US6011646A (en) | 1998-02-20 | 2000-01-04 | The Regents Of The Unviersity Of California | Method to adjust multilayer film stress induced deformation of optics |
| FR2777890B1 (fr) * | 1998-04-22 | 2000-12-29 | Roussy Inst Gustave | Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer |
| US6261679B1 (en) | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
| BR9912070A (pt) | 1998-07-13 | 2001-04-10 | Expression Genetics Inc | Análogo de poliéster de poli-l-lisina como um solúvel, veìculo de distribuição de gene biodegradável |
| US6280937B1 (en) * | 1998-08-14 | 2001-08-28 | Rigel Pharmaceuticals, Inc. | Shuttle vectors |
| BR9914891A (pt) | 1998-10-27 | 2001-07-17 | Mayo Foundation | Processos para aperfeiçoamento de cura de ferimento |
| CA2348823A1 (en) * | 1998-12-02 | 2000-06-08 | I.D.M. Immuno-Designed Molecules | New oligomeric conjugates liable to transfer biological molecules into cells |
| WO2000034308A2 (en) | 1998-12-10 | 2000-06-15 | Washington University | Protein transduction system and methods of use thereof |
| EP1159418A2 (en) * | 1998-12-11 | 2001-12-05 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
| US7056656B1 (en) | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
| ES2160485B1 (es) | 1999-04-23 | 2002-05-16 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. |
| US20030236214A1 (en) * | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
| EP1074625A3 (en) * | 1999-06-14 | 2002-01-02 | Pfizer Products Inc. | DNA vaccine against feline immunodeficiency virus |
| US6492152B1 (en) * | 1999-06-15 | 2002-12-10 | The Board Of Regents Of The University Of Oklahoma | Core 1 β3-galactosyl transferases and methods of use thereof |
| US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
| US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| MXPA02001857A (es) | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
| US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| WO2001018248A2 (en) * | 1999-09-03 | 2001-03-15 | The University Of Iowa Research Foundation | Quorum sensing signaling in bacteria |
| US6297056B1 (en) * | 1999-10-12 | 2001-10-02 | Pioneer Hi-Bred International, Inc. | Brassica transformation via microprojectile bombardment |
| US6610820B1 (en) | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| US6670322B2 (en) | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| EP1164796B1 (en) * | 2000-06-14 | 2006-12-20 | Eads Astrium Sas | Process and system for video on demand |
| US20040220100A1 (en) | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| CA2797652C (en) | 2000-07-21 | 2016-03-08 | Revance Therapeutics, Inc. | Multi-component biological transport systems |
| US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
| US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
| US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| WO2002065986A2 (en) | 2001-02-16 | 2002-08-29 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
| US20030086256A1 (en) | 2001-11-02 | 2003-05-08 | Heart Linked Corporation Ltd | Compact light weight energy-efficient illumination module for integrated portable applications |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| MXPA04005611A (es) | 2001-12-11 | 2005-04-19 | Cellgate Inc | Reactivos y conjugados de transporte de guanidinio. |
| WO2003102166A2 (en) | 2002-02-26 | 2003-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
| US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| US7459164B2 (en) | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
| AU2003237346A1 (en) | 2002-05-31 | 2003-12-19 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US7071167B2 (en) | 2002-11-13 | 2006-07-04 | L'oreal | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
| US6866856B2 (en) | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
| US7482016B2 (en) | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
| US20040192754A1 (en) | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
| WO2004084839A2 (en) | 2003-03-24 | 2004-10-07 | Cady Roger K | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
| PT1729821E (pt) | 2004-03-03 | 2013-10-23 | Revance Therapeutics Inc | Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas |
| AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| US7691381B2 (en) | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
| US20060040882A1 (en) | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
| BRPI0513850A (pt) | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| US20060024331A1 (en) | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
| BRPI0608249A2 (pt) | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
-
2001
- 2001-07-20 CA CA2797652A patent/CA2797652C/en not_active Expired - Lifetime
- 2001-07-20 PT PT100131358T patent/PT2364734T/pt unknown
- 2001-07-20 US US09/910,432 patent/US7807780B2/en not_active Expired - Fee Related
- 2001-07-20 PT PT1963739T patent/PT1301213T/pt unknown
- 2001-07-20 NZ NZ523719A patent/NZ523719A/en not_active IP Right Cessation
- 2001-07-20 EP EP01963739.6A patent/EP1301213B1/en not_active Expired - Lifetime
- 2001-07-20 IL IL15404401A patent/IL154044A0/xx unknown
- 2001-07-20 JP JP2002513506A patent/JP5610659B2/ja not_active Expired - Fee Related
- 2001-07-20 DK DK01963739.6T patent/DK1301213T3/en active
- 2001-07-20 WO PCT/US2001/023072 patent/WO2002007773A2/en not_active Ceased
- 2001-07-20 CA CA2416289A patent/CA2416289C/en not_active Expired - Fee Related
- 2001-07-20 AU AU8466501A patent/AU8466501A/xx active Pending
- 2001-07-20 EP EP10013135.8A patent/EP2364734B1/en not_active Expired - Lifetime
- 2001-07-20 ES ES01963739.6T patent/ES2617692T3/es not_active Expired - Lifetime
- 2001-07-20 DK DK10013135.8T patent/DK2364734T3/en active
- 2001-07-20 AU AU2001284665A patent/AU2001284665B2/en not_active Ceased
-
2003
- 2003-01-20 IL IL154044A patent/IL154044A/en active IP Right Grant
- 2003-01-20 ZA ZA200300513A patent/ZA200300513B/en unknown
-
2006
- 2006-09-08 AU AU2006209264A patent/AU2006209264A1/en not_active Abandoned
-
2009
- 2009-12-24 AU AU2009253761A patent/AU2009253761B2/en not_active Expired
-
2010
- 2010-10-04 US US12/897,188 patent/US20110020229A1/en not_active Abandoned
-
2011
- 2011-12-07 JP JP2011268234A patent/JP5797104B2/ja not_active Expired - Lifetime
-
2017
- 2017-03-16 CY CY20171100331T patent/CY1118963T1/el unknown
- 2017-11-08 CY CY20171101168T patent/CY1119742T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012097094A5 (enExample) | ||
| JP2004513075A5 (enExample) | ||
| JP7368522B2 (ja) | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 | |
| US10253099B2 (en) | Conjugates of proteins and multivalent cell-penetrating peptides and their uses | |
| Fella et al. | Amine-reactive pyridylhydrazone-based PEG reagents for pH-reversible PEI polyplex shielding | |
| He et al. | Combinatorial optimization of sequence-defined oligo (ethanamino) amides for folate receptor-targeted pDNA and siRNA delivery | |
| ES2536996T3 (es) | Anticuerpos biespecíficos de unión a digoxigenina | |
| ES2876939T3 (es) | Péptidos penetradores de células que tienen un dominio hidrófobo central | |
| JP2012509900A5 (enExample) | ||
| IL276464B1 (en) | Methods and compositions for administering therapeutic protein | |
| US20030203865A1 (en) | Lipid-comprising drug delivery complexes and methods for their production | |
| Kasala et al. | Utilizing adenovirus vectors for gene delivery in cancer | |
| JP2012529891A5 (enExample) | ||
| CN102892420A (zh) | 用于递送寡核苷酸的新型单一化学实体和方法 | |
| Lin et al. | Chemical evolution of amphiphilic xenopeptides for potentiated Cas9 ribonucleoprotein delivery | |
| ES2996886T3 (en) | Rodents comprising a humanized asgr1 locus | |
| CN103221549A (zh) | 用于递送寡核苷酸的新型简单化学实体和方法 | |
| JP2010514779A5 (enExample) | ||
| JP2014508521A (ja) | 細胞内へのカーゴ送達のためのシステム | |
| Ullah et al. | Trileucine residues in a ligand-CPP-based siRNA delivery platform improve endosomal escape of siRNA | |
| Rao et al. | Evaluation of the transfection property of a peptide ligand for the fibroblast growth factor receptor as part of PEGylated polyethylenimine polyplex | |
| ES2565344T3 (es) | Semianticuerpos con auto-ensamblaje | |
| McKay et al. | Secretin-mediated gene delivery, a specific targeting mechanism with potential for treatment of biliary and pancreatic disease in cystic fibrosis | |
| US20090253206A1 (en) | Nuclear transport agent and method for producing said agent | |
| US9974818B2 (en) | PPSA and Pspa polymer-virus complex and pharmaceutical compositions comprising the same |